A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects

Trial Profile

A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Aravive S6 (Primary)
  • Indications Acute myeloid leukaemia; Solid tumours
  • Focus Adverse reactions
  • Sponsors Aravive Biologics
  • Most Recent Events

    • 08 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 29 Jan 2018 According to a WuXi Biologics media release, the company has successfully filed an IND application and expects to begin this trial in the first quarter of 2018.
    • 23 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top